ClinicalTrials.gg
TerminatedNCT01220128INDUCTUpdated May 25, 2021Results posted

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

A Phase 2 interventional study of GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A and Placebo in Neoplasms, Breast, sponsored by GlaxoSmithKline. Terminated at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Study termination due to negative Ph III of another study product from same technology platform.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies testing Aromatase inhibitors in Breast Neoplasms — 53 open to participants now, 81 under way, 22 of them phase 3. A drug class: Aromatase inhibitors · Breast Neoplasms.

Enrollment
212th of 341
66 · median 112
Started
2011
with 9 others
Phase 2
166 of 349
36 open now
Registered
157th of 349
by date

Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, this one is the 212th largest by enrollment of the 341 interventional ones that give a count, is one of 10 that started in 2011, is one of 166 in phase 2, and was the 157th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

53 of the 349 studies testing Aromatase inhibitors in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

48 more — sign in →

By country, each count listing its studies:

All 53 open studies →

About Aromatase inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies testing Aromatase inhibitors in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.

Read the detailed description

The study will be conducted in two consecutive segments (Phase I and Phase II), each with specific objectives. Active follow-up will be for three years.

Patients in this study will be allocated to cohorts as below. Cohort A will include postmenopausal patients with hormone receptor-positive breast cancer who receive aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of 6 or 8 doses of WT1 anti-cancer immunotherapy (WT1 ASCI)/placebo starting on Day 0. AI treatment will be administered daily for duration of either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).

Cohort B will include breast cancer patients who will receive neoadjuvant chemotherapy concurrently with administration of WT1 ASCI/placebo starting on Day 0. Neoadjuvant chemotherapy in Cohort B will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly or 12-weekly taxane administrations without trastuzumab.

Cohort C will include patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who will receive neoadjuvant trastuzumab (Herceptin) therapy combined with chemotherapy concurrently with administration of WT1 ASCI/placebo starting on Day 0. Neoadjuvant chemotherapy in Cohort C will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly or 12-weekly taxane administrations with trastuzumab.

Cohorts D and E will include patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who will receive neoadjuvant chemotherapy. For patients in these Cohorts D and E, WT1 ASCI/placebo (placebo applicable only for Cohort E patients) will be administered on Day 14 of each three-weekly cycle of chemotherapy. Neoadjuvant chemotherapy in Cohorts D and E will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly taxane administrations without trastuzumab. Enrolment in Cohort E will be conditional on the absence of a safety signal and on the adequate induction of an immune response by the WT1 ASCI in Cohort D (defined as >= 40% response rate based on post-Dose 4 anti-WT1 antibody responses in at least six patients). If this criterion is met, 60 patients (40 receiving WT1 ASCI and 20 placebo) with identical eligibility criteria will be enrolled into Cohort E. In case no adequate safety and/or immunogenicity will be obtained in Cohort D, recruitment in Cohort E will not be initiated.

The protocol has been updated following Protocol Amendment 4, April 2013, leading to the update of the study design.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • WT1
  • neoadjuvant
  • tumor antigen
  • immunotherapy
  • breast cancer
  • adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is ≥ 18 years of age at the time the to screening has been obtained.
  • The patient has proven T1 with lymph node involvement or T2-T4c, any N, M0 primary invasive breast cancer, confirmed by core needle .

Isolated supraclavicular lymph node involvement is allowed.

  • The patient's tumor shows WT1 antigen expression.
  • The patient has one of the following histologically confirmed breast cancer subtypes:

    • Estrogen receptor and/or progesterone positive tumor.
    • Human epidermal growth factor receptor 2 ()-overexpressing breast cancer.
    • HER2-negative breast cancer.
  • (performance status of 0 or 1 at the time of study treatment allocation.
  • Baseline of ≥ 50% as measured within six weeks prior to study treatment allocation by echocardiography or multi-gated acquisition(MUGA)scan.
  • The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation)::

    • : Within normal range according to institutional standards.
    • Absolute leukocyte count: Within normal range according to institutional standards.
    • Absolute lymphocyte count: Within normal range according to institutional standards.
    • count: Within normal range according to institutional standards
    • : ≤ 2.5 x (ULN)
    • Aspartate aminotransferase: ≤ 2.5 x ULN
    • Total : ≤ 1.5 x ULN. In the case of known Gilbert's syndrome ≤ 2 x ULN
    • Serum creatinine: 1.5 x ULN
    • Calculated : > 50 mL/min
  • A female patient of may be enrolled in the study, if the patient:

    • has practiced adequate for 30 days prior to study product administration, and
    • has a negative pregnancy test within one week prior to treatment allocation and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the study product administration series.In view of the investigator, the patient can and will comply with the requirements of the protocol.
  • Written informed consent has been obtained from the patient prior to performance of any study specific procedure.

Exclusion criteria

Exclusion Criteria:

  • The patient has inflammatory breast cancer, which is defined as erythema of the breast and/or documented dermal lymphatic invasion.
  • Diagnosis established by incisional .
  • Prior and concomitant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers, endocrine therapy, and radiotherapy, unless authorized specifically by the protocol.
  • The patient is known to be -positive.
  • The patient has symptomatic disease such as, but not limited to multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.
  • The patient is known to have difficult-to-control hypertension, coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on or previous myocardial infarction or congestive heart failure.
  • The patient has a history of allergic reactions likely to be exacerbated by any component of the product used in the study.
  • The patient has other concurrent severe medical problems, unrelated to the , that would significantly limit full compliance with the study or expose the patient to unacceptable risk.
  • The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
  • The patient has psychiatric or addictive disorders that may compromise his/her ability to give or to comply with the study procedures.
  • The patient has received any investigational or non-registered product within 30 days preceding the first dose of study products or planned use during the study period.
  • The patient requires concomitant treatment with any agents or with systemic prescribed for chronic treatment.
  • The patient has a significant disorder of coagulation or receives treatment with warfarin derivatives or heparin. Patients receiving individual doses of low molecular weight heparin outside of 24 hours prior to WT1-A10 + AS15 ASCI/placebo administration are eligible. Patients receiving prophylactic antiplatelet medications e.g. low-dose aspirin, and without a clinically-apparent bleeding tendency are eligible.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Cohort A-GSK2302024A Group

    This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.

    Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: Aromatase inhibitor

  • Placebo comparator
    Cohort A-Placebo Group

    This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.

    Drug: Placebo · Drug: Aromatase inhibitor · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel

  • Experimental
    Cohort B-GSK2302024A Group

    This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

    Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel

  • Placebo comparator
    Cohort B-Placebo Group

    This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

    Drug: Placebo · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel

  • Experimental
    Cohort C-GSK2302024A Group

    This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

    Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Carboplatin AUC · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Trastuzumab

  • Placebo comparator
    Cohort C-Placebo Group

    This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

    Drug: Placebo · Drug: 5-Fluorouracil · Drug: Carboplatin AUC · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Trastuzumab

  • Experimental
    Cohort D-GSK2302024A-D14 Group

    This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.

    Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel

Interventions

  • BiologicalGSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A

    6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.

    Also known as: WT1 ASCI

  • DrugPlacebo

    6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.

  • This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • DrugCarboplatin AUC

    Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

  • Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.

This study also gives Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Severe Toxicities

    Severe toxicity was defined as follows: - A Grade 3 or higher toxicity that is related or possibly related to the combined administration of standard treatment and GSK2302024A/placebo - A decrease in Left Ventricular Ejection Fraction (LVEF) from baseline with ≥ 10 points and at \< 50% that is related or possibly related to the combined administration of treatment and that is confirmed by a second LVEF assessment within approximately 3 weeks. - A Grade 2 or higher cardiac ischemia/infarction that is related or possibly related to the combined administration of standard treatment and GSK2302024A /placebo. - A Grade 2 or higher allergic reaction occurring within 24 hours following the administration. - A Grade 3 or higher blood/bone marrow toxicity that was considered as related or possibly related to the combined Administration. - A decrease in renal function at the time of administration that was considered as related or possibly related.

    Time frame: From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)

  2. Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response

    For initially seronegative patients: post-administration antibody concentration ≥ 9 EU/mL For initially seropositive patients: post-administration antibody concentration ≥ 2 fold the pre-administration antibody concentration.

    Time frame: At post-GSK2302024A/placebo Dose 4 (Week 13)

  3. Number of Patients With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.

    Time frame: During the treatment period and up to 30 days post last administration

  4. Number of Subjects With Serious Adverse Events SAE(s)

    A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, causes disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient. In this study, an event which was part of the natural course of the disease under study (i.e., disease progression/recurrence) was captured in the study/as an efficacy measure. Therefore it was not reported as an SAE. Progression/recurrence of the tumor was recorded in the clinical assessments in the electronic case report form (eCRF). Death due to progressive disease was recorded on a specific form in the eCRF but not as an SAE.

    Time frame: From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)

  5. Number of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  6. Number of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  7. Number of Subjects With Anemia, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  8. Number of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  9. Number of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  10. Number of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  11. Number of Subjects With Hemoglobin Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  12. Number of Subjects With Hypercalcemia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  13. Number of Subjects With Hyperkalemia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  14. Number of Subjects With Hypernatremia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  15. Number of Subjects With Hypoalbuminemia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  16. Number of Subjects With Hypocalcemia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  17. Number of Subjects With Hypokalemia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  18. Number of Subjects With Hyponatremia Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and post 30 days post last administration

  19. Number of Subjects With Lymphocyte Count Decreased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  20. Number of Subjects With Lymphocyte Count Increased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  21. Number of Subjects With Neutrophil Count Decreased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  22. Number of Subjects With Platelet Count Decreased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  23. Number of Subjects With White Blood Cell Decreased Abnormality, by CTCAE Maximum Grade

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  24. Number of Patients With Adverse Events (AEs), by CTCAE Maximum Grade Reported

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  25. Number of Subjects With Adverse Events (AEs) Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  26. Number of Subjects With Serious Adverse Events (SAEs), by CTCAE Maximum Grade Reported

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  27. Number of Subjects With Serious Adverse Events (SAEs), Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported

    Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

    Time frame: During the treatment period and up to 30 days post last administration

  28. Number of Subjects With Breast Cancer Pathological Response

    The pathological response in lymph nodes was evaluated by presence or absence of tumor cells by histopathological examination. Partial responses mark the disappearance of tumor cells, with only small clusters or dispersed cells remaining (more than 90% loss) while complete response indicate no identifiable malignant cells. However, ductal carcinoma in situ may be present.

    Time frame: During the treatment period, up to Week 26/32

07

Results

Posted May 25, 2017

Participant flow

Out of the 66 enrolled patients, 6 patients did not receive study product doses and were hence excluded prior to study start.

Participant flow — Overall Study
MilestoneCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Started157961148
Completed116661143
Not completed4130005
Withdrew: Progressive disease0020000
Withdrew: Sponsor study termination0100001
Withdrew: Adverse event, serious fatal2000001
Withdrew: Adverse event, non-fatal1000003
Withdrew: Other0010000
Withdrew: Consent withdrawn by subject1000000

Outcome measures

PrimaryNumber of Subjects With Severe Toxicities

Severe toxicity was defined as follows: - A Grade 3 or higher toxicity that is related or possibly related to the combined administration of standard treatment and GSK2302024A/placebo - A decrease in Left Ventricular Ejection Fraction (LVEF) from baseline with ≥ 10 points and at \< 50% that is related or possibly related to the combined administration of treatment and that is confirmed by a second LVEF assessment within approximately 3 weeks. - A Grade 2 or higher cardiac ischemia/infarction that is related or possibly related to the combined administration of standard treatment and GSK2302024A /placebo. - A Grade 2 or higher allergic reaction occurring within 24 hours following the administration. - A Grade 3 or higher blood/bone marrow toxicity that was considered as related or possibly related to the combined Administration. - A decrease in renal function at the time of administration that was considered as related or possibly related.

Time frame:
From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
Reported as:
Number · Subjects
Number of Subjects With Severe Toxicities
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Number of Subjects With Severe Toxicities0010100
PrimaryNumber of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response

For initially seronegative patients: post-administration antibody concentration ≥ 9 EU/mL For initially seropositive patients: post-administration antibody concentration ≥ 2 fold the pre-administration antibody concentration.

Time frame:
At post-GSK2302024A/placebo Dose 4 (Week 13)
Reported as:
Number · Subjects
Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response10000602
PrimaryNumber of Patients With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Patients With Adverse Events (AEs)
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Number of Patients With Adverse Events (AEs)155961147
PrimaryNumber of Subjects With Serious Adverse Events SAE(s)

A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, causes disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient. In this study, an event which was part of the natural course of the disease under study (i.e., disease progression/recurrence) was captured in the study/as an efficacy measure. Therefore it was not reported as an SAE. Progression/recurrence of the tumor was recorded in the clinical assessments in the electronic case report form (eCRF). Death due to progressive disease was recorded on a specific form in the eCRF but not as an SAE.

Time frame:
From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events SAE(s)
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Number of Subjects With Serious Adverse Events SAE(s)3042515
PrimaryNumber of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 012584621
Grade 12112522
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown1100005
PrimaryNumber of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 010586731
Grade 15110412
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Anemia, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Anemia, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 012710002
Grade 12074732
Grade 21000410
Grade 30010000
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 012486712
Grade 13210431
Grade 21000000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0155961123
Grade 10100000
Grade 20000010
Grade 30000010
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0114851033
Grade 14211110
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown4100005
PrimaryNumber of Subjects With Hemoglobin Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hemoglobin Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0156961144
Grade 10100000
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Subjects With Hypercalcemia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hypercalcemia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0143861143
Grade 11310000
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown3100005
PrimaryNumber of Subjects With Hyperkalemia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hyperkalemia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0155761043
Grade 10110100
Grade 20010000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Hypernatremia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hypernatremia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0144961043
Grade 11200000
Grade 20000100
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Hypoalbuminemia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hypoalbuminemia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 013695933
Grade 11001210
Grade 21000000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Hypocalcemia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hypocalcemia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0126541033
Grade 13031110
Grade 20011000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Hypokalemia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hypokalemia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0156961043
Grade 10000100
Grade 20010000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Hyponatremia Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and post 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Hyponatremia Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0156561143
Grade 10040000
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown0100005
PrimaryNumber of Subjects With Lymphocyte Count Decreased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Lymphocyte Count Decreased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 09400211
Grade 15232311
Grade 21152512
Grade 30012110
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Subjects With Lymphocyte Count Increased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Lymphocyte Count Increased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0157961144
Grade 10000000
Grade 20000000
Grade 30000000
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Subjects With Neutrophil Count Decreased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Neutrophil Count Decreased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 0126751030
Grade 13011100
Grade 20110001
Grade 30000010
Grade 40000003
Grade Unknown0000004
PrimaryNumber of Subjects With Platelet Count Decreased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Platelet Count Decreased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 014685522
Grade 11111522
Grade 20000100
Grade 30000000
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Subjects With White Blood Cell Decreased Abnormality, by CTCAE Maximum Grade

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With White Blood Cell Decreased Abnormality, by CTCAE Maximum Grade
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Grade 013763720
Grade 12022411
Grade 20011010
Grade 30000003
Grade 40000000
Grade Unknown0000004
PrimaryNumber of Patients With Adverse Events (AEs), by CTCAE Maximum Grade Reported

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Patients With Adverse Events (AEs), by CTCAE Maximum Grade Reported
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Any AE(s) Grade 16100000
Any AE(s) Grade 26460432
Any AE(s) Grade 33005301
Any AE(s) Grade 40021414
Any AE(s) Grade 50010000
Any AE(s)155961147
PrimaryNumber of Subjects With Adverse Events (AEs) Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Adverse Events (AEs) Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Any related AE(s) Grade 17200502
Any related AE(s) Grade 24030114
Any related AE(s) Grade 31000100
Any related AE(s) Grade 40000000
Any related AE(s) Grade 50000000
Any related AE(s)12230716
PrimaryNumber of Subjects With Serious Adverse Events (SAEs), by CTCAE Maximum Grade Reported

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs), by CTCAE Maximum Grade Reported
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Any SAE(s) Grade 10000000
Any SAE(s) Grade 21010000
Any SAE(s) Grade 32001101
Any SAE(s) Grade 40021414
Any SAE(s) Grade 50010000
Any SAE(s)3042515
PrimaryNumber of Subjects With Serious Adverse Events (SAEs), Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported

Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).

Time frame:
During the treatment period and up to 30 days post last administration
Reported as:
Number · Subjects
Number of Subjects With Serious Adverse Events (SAEs), Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Any related SAE(s) Grade 10000000
Any related SAE(s) Grade 21000000
Any related SAE(s) Grade 30000100
Any related SAE(s) Grade 40000000
Any related SAE(s) Grade 50000000
Any related SAE(s)1000100
PrimaryNumber of Subjects With Breast Cancer Pathological Response

The pathological response in lymph nodes was evaluated by presence or absence of tumor cells by histopathological examination. Partial responses mark the disappearance of tumor cells, with only small clusters or dispersed cells remaining (more than 90% loss) while complete response indicate no identifiable malignant cells. However, ductal carcinoma in situ may be present.

Time frame:
During the treatment period, up to Week 26/32
Reported as:
Number · Subjects
Number of Subjects With Breast Cancer Pathological Response
SubjectsCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
Partial respose4353313
Complete response0002631

Adverse events

Collected over AEs were reported during the treatment period and up to 30 days post last administration. SAEs during the entire study period (Week 0 to Week 26/32).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A-GSK2302024A Group0/15 (0%)3/15 (20%)15/15 (100%)
Cohort A-Placebo Group0/7 (0%)0/7 (0%)5/7 (71.4%)
Cohort B-GSK2302024A Group1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Cohort B-Placebo Group0/6 (0%)2/6 (33.3%)6/6 (100%)
Cohort C-GSK2302024A Group0/11 (0%)5/11 (45.5%)11/11 (100%)
Cohort C-Placebo Group0/4 (0%)1/4 (25%)4/4 (100%)
Cohort D-GSK2302024A-D14 Group0/8 (0%)5/8 (62.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
NeutropeniaBlood and lymphatic system disorders0/150/71/91/64/110/43/8
Febrile neutropeniaBlood and lymphatic system disorders0/150/71/91/61/111/42/8
DiarrhoeaGastrointestinal disorders0/150/70/90/62/110/40/8
LeukopeniaBlood and lymphatic system disorders0/150/71/90/61/110/41/8
StomatitisGastrointestinal disorders0/150/70/90/60/110/41/8
MyalgiaMusculoskeletal and connective tissue disorders0/150/70/90/60/110/41/8
DeathGeneral disorders0/150/71/90/60/110/40/8
CholecystitisHepatobiliary disorders0/150/71/90/60/110/40/8
HyponatraemiaMetabolism and nutrition disorders0/150/71/90/60/110/40/8
NauseaGastrointestinal disorders0/150/70/90/61/110/40/8
Most frequent other events
Showing 10 of 53
Most frequent other events
EventCohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 Group
FatigueGeneral disorders3/151/78/94/67/114/42/8
AlopeciaSkin and subcutaneous tissue disorders0/150/79/95/68/113/43/8
NauseaGastrointestinal disorders2/150/76/90/68/112/43/8
Injection site painGeneral disorders4/150/70/90/64/110/44/8
Mucosal inflammationGeneral disorders0/150/73/90/63/112/40/8
LeukopeniaBlood and lymphatic system disorders0/150/70/93/60/110/42/8
Peripheral sensory neuropathyNervous system disorders0/151/72/90/65/112/40/8
DysgeusiaNervous system disorders0/150/72/93/60/110/42/8
PruritusSkin and subcutaneous tissue disorders0/150/70/90/60/112/40/8
ArthralgiaMusculoskeletal and connective tissue disorders3/152/72/90/63/112/40/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 GroupTotal
Mean69.3 ± 10.470.9 ± 7.149.3 ± 15.660.7 ± 9.852.9 ± 10.653.3 ± 6.249.6 ± 8.758.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A-GSK2302024A GroupCohort A-Placebo GroupCohort B-GSK2302024A GroupCohort B-Placebo GroupCohort C-GSK2302024A GroupCohort C-Placebo GroupCohort D-GSK2302024A-D14 GroupTotal
Female15796114860
Male00000000
08

Study locations

36 sites
  • GSK Investigational Site
    Newark, Delaware 19713, United States
  • GSK Investigational Site
    Plantation, Florida 33324, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109-5848, United States
  • GSK Investigational Site
    Bend, Oregon 97701, United States
  • GSK Investigational Site
    Memphis, Tennessee 38120, United States
  • GSK Investigational Site
    Amarillo, Texas 79106, United States
  • GSK Investigational Site
    Spokane, Washington 99208, United States
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Namur, 5000, Belgium
  • GSK Investigational Site
    Lyon Cedex 08, 69373, France
  • GSK Investigational Site
    Saint-Herblain, 44805, France
  • GSK Investigational Site
    Tuebingen, Baden-Wuerttemberg 72076, Germany
  • GSK Investigational Site
    Erlangen, Bayern 91054, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Rostock, Mecklenburg-Vorpommern 18059, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44137, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45136, Germany
  • GSK Investigational Site
    Chemnitz, Sachsen 09116, Germany
  • GSK Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • GSK Investigational Site
    Napoli, Campania 80131, Italy
  • GSK Investigational Site
    Aviano (PN), Friuli-Venezia-Giulia 33081, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20141, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Torino, Piemonte 10126, Italy
  • GSK Investigational Site
    Trento, Trentino-Alto Adige 38100, Italy
  • GSK Investigational Site
    Ryazan, 390011, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197022, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 197758, Russian Federation
  • GSK Investigational Site
    Belfast, BT9 7AB, United Kingdom
  • GSK Investigational Site
    Bournemouth, BH7 7DW, United Kingdom
  • GSK Investigational Site
    Derby, DE22 3DT, United Kingdom
  • GSK Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • GSK Investigational Site
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Publications

  • Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching PA, Campone M, Bachelot T, Krivorotko P, Chan S, Ferro A, Schwartzberg L, Gillet M, De Sousa Alves PM, Wascotte V, Lehmann FF, Goss P. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Res Treat. 2017 Apr;162(3):479-488. doi: 10.1007/s10549-017-4130-y. Epub 2017 Feb 7. PubMed 28176175 ↗

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site (click on the link provided below).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2011 to primary completion in Nov 2014, 43 months.

Results were first posted in May 2017, 2 years 6 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2010
First posted
Oct 13, 2010
StartActual
Apr 11, 2011
Primary completionActual
Nov 14, 2014
CompletionActual
Nov 14, 2014
Results delay requested
Mar 12, 2015
Results first posted
May 25, 2017
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01220128
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 13, 2010
Start date
Apr 11, 2011
Primary completion
Nov 14, 2014
Completion
Nov 14, 2014
Results posted
May 25, 2017
Last update
May 25, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aromatase inhibitors · Fluorouracil · Cyclophosphamide · Docetaxel · Doxorubicin · Epirubicin · Paclitaxel

Start the discussion